Equities researchers at StockNews.com started coverage on shares of InspireMD (NYSE:NSPR – Get Free Report) in a report issued on Sunday. The firm set a “sell” rating on the stock.
InspireMD Price Performance
Shares of NSPR opened at $2.72 on Friday. InspireMD has a one year low of $1.81 and a one year high of $3.85. The company’s fifty day moving average price is $2.76 and its 200 day moving average price is $2.51. The company has a market capitalization of $67.90 million, a PE ratio of -3.58 and a beta of 0.90.
InspireMD (NYSE:NSPR – Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The business had revenue of $1.74 million for the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same quarter in the previous year, the company earned ($0.24) EPS. Analysts anticipate that InspireMD will post -0.82 earnings per share for the current year.
Institutional Trading of InspireMD
InspireMD Company Profile
InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.
Recommended Stories
- Five stocks we like better than InspireMD
- What Do S&P 500 Stocks Tell Investors About the Market?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- What is a Stock Market Index and How Do You Use Them?
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.